FAPI PET for Lung Fibrosis

Summary

This is a prospective exploratory biodistribution study in patients with interstitial lung disease (ILD). The purpose of this research study is to determine where and to which degree the FAPI tracer (68Ga-FAPI-46) accumulates in normal and fibrotic lung tissues of patients with interstitial lung disease. The study will include patients with interstitial lung disease who have or will initiate a new ILD medication OR will undergo tissue biopsy or surgery of the lung. The study will include 30 patients, the upper limit for PET imaging studies conducted under the Radioactive Drug Research Committee (RDRC) purview. Participants will be injected with up to 7 mCi of 68-GaFAPi and will undergo one PET/CT scan and one High Resolution CT of the lungs. The study is sponsored by Ahmanson Translational Theranostic Division at UCLA.

Timeline

Start

2021-11-16

Primary completion

2026-12

Completion

2026-12

Publications

• Hotta M, Kim GHJ, Rerkpichaisuth V, Teng PY, Armstrong WR, Carlucci G, Dahlbom M, Abtin F, Lari SM, Fishbein GA, Czernin J, Volkmann ER, Weigt SS, Calais J. Correlation of FAPI PET Uptake with Immunohistochemistry in Explanted Lungs from Patients with Advanced Interstitial Lung Disease. J Nucl Med. 2024 Nov 1;65(11):1789-1794. doi: 10.2967/jnumed.124.268351.

Drugs

Indications